Trial Profile
A Pilot Study of Rosiglitazone in Patients With Incurable Differentiated Thyroid Cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 24 Jun 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.
- 14 Jun 2008 Expected completion date for this trial has been extended from Jan 2008 to Jun 2010 reported by ClinicalTrial.gov.
- 30 Aug 2005 New trial record.